Study of Typical conditions for the growth of bacteria, Acinetobacter baumannii isolated from pathological cases.

Husseini, Najeeb M.; Abdul-Rahman, Ibrahim A.; Hussien, Abd Al Wahab B.

doi:10.37652/juaps.2017.176984

	Study of Typical conditions for the growth of bacteria, Acinetobacter baumannii isolated from pathological cases.
Journal of University of Anbar for Pure Science
Article 34, Volume 9, Issue 2, 2015, Pages 96-101 PDF (1.5 M)
Document Type: Research Paper
DOI: 10.37652/juaps.2017.176984
Authors
Najeeb M. Husseini^* ¹; Ibrahim A. Abdul-Rahman²; Abd Al Wahab B. Hussien²
¹University of Anbar
²University of Fallujah, College of Veterinary Medicine
Abstract
In this study, two hundred clinical samples have been chosen to isolate Acinetobacter baumanni from patients whose suffering from different infections, which included swabs from sputum, urine, wounds and burns. VITEK 2 COMPACT system has been used to diagnose percentage of bacteria in the samples and the highest rate was wounds infection, urinary tract infection and burns infection and the percentage 20%, 10% and 6.6% respectively. Moreover Several conditions which could have effect on A. baumannii growth have been studied which included size of the vaccine, temperature, pH and incubation time. given the IAN5 isolation best growth after studying affecting the growth and the following conditions where the best size for inoculum 4 ml / L and 40 ° C for temperature , and 7.5 for pH and 48 hours for the incubation time .

References
1: Falagas, M. E., P. I. Rafailidis, D. K. Matthaiou, S. Virtzili, D. Nikita, and A. Michalopoulos. 2008. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter genospecies 13 TU infections: Characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents32:450-4. 2: Paterson, D. 2006. The epidemiological profile of infections with multidrug resistant Pseudomonas aeruginosa and Acinetobacter species. Clinicalinfectious diseases 43:S43-S48. 3:Giamarellou H., Antoniadou A. and Kanellakopoulou K. (2008). Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents, 32:106-19. 4: Fournier, P. E., and H. Richet. 2006. The epidemiology and control of Acinetobacter genospecies 13 TU in health care facilities. Clin Infect Dis42:692. 5: Zhanel, G.G., Lawson, C.D., Adam, H., Schweizer, F., Zelenitsky, S., Lagace-Wiens, P.R., Denisuik, A., Rubinstein, E., Gin, A.S., et al,( 2013). Ceftazidime–avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs 73, 159–177. 6: Ting, C., Jun, A., Shun, Z.,( 2013). Detection of the common resistance genes in Gram-negative bacteria using gene chip technology. Indian. 7: Rezaee, M.A., Pajand, O., Nahaei, M.R., Mahdian, R., Aghazadeh, M., Ghojazadeh, M., Hojabri, Z., (2013). Prevalence of Ambler class A beta-lactamases and ampC expression in cephalosporin-resistant isolates of Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 76, 330–334. 8: Peymani, A., Nahaei, M.R., Farajnia, S., Hasani, A., Mirsalehian, A., Sohrabi, N., Abbasi, L.,( 2011). High prevalence of metallo-beta-lactamase-producing Acinetobacter baumannii in a teaching hospital in Tabriz, Iran. Jpn. J. Infect. Dis. 64, 69–71. 9: Shahcheraghi, F., Abbasalipour, M., Feizabadi, M., Ebrahimipour, G., Akbari, N.,( 2011). Isolation and genetic characterization of metallo-beta-lactamase and carbapenamase producing strains of Acinetobacter baumannii from patients at Tehran hospitals. Iran. J. Microbiol. 3, 68–74. 10: Pfeifer, Y., Cullik, A., Witte, W., (2010). Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int. J. Med. Microbiol. 300, 371–379. 11: Kim, Y., et al. (2014). "In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment." Diagnostic Microbiology and Infectious Disease 79(3): 362-366.
Statistics Article View: 279 PDF Download: 138